For those presenting with proptosis within 36 months, unilateral TED probably represents an early stage of the disease-initially limited to only one eye, and the contralateral proptosis is due to ...
Sling Therapeutics’ oral challenger to Amgen’s intravenous Tepezza has hit the mark in a phase 2b/3 thyroid eye disease (TED) ...
TED is a rare autoimmune disorder in which the muscles and fatty tissues behind the eye become inflamed, causing the eyes to ...
For patients with mild TED, supportive care including ocular surface management offers substantial benefit. Selenium supplementation has also been examined for the treatment of mild, active TED.
The trial confirmed linsitinib's favorable safety profile, with no QTc prolongation and manageable adverse events. Late-stage ...
Linsitinib is an oral small molecule that inhibits the activity of insulin-like growth factor-1 receptor (IGF-1R). It is believed that inhibition of IGF-1R may help reduce orbital inflammation and ...
COVID-19 vaccines were not associated with increased risk for thyroid diseases but were associated with increased risk for exacerbated hypothyroidism.
Madam Goh, now 62, had thyroid eye disease (TED), a rare autoimmune disease in which the eye muscles and fatty tissue behind the eyes become inflamed, pushing the eyes forward or causing the eyes and ...
Acelyrin (NASDAQ:SLRN) shares lost ~32% after the clinical-stage biotech announced new results from a Phase 2 trial for lonigutamab, an injectable targeted at thyroid eye disease (TED) and disclosed ...
Topline results have been announced from a Phase 2/3 trial assessing linsitinib for the treatment of active, moderate to ...
Modifiable risk factors for thyroid eye disease include smoking habits and patient endocrine status. Avoid treating patients with active TED with radioactive iodine ablation. KOLOA, Hawaii ...
In 2022, the total prevalent cases of thyroid eye disease (TED) in the United States were approximately 1,012,000, making up about 42% of the total 7MM population. . Germany accounted for around ...